The future of cancer therapy should include different approaches: the recovery of specific immune immunosuppressive pathways in the anti-tumor process in order to understand the mechanisms of action active in the tumor microenvironment and the cooperation with target therapy with a consolidated efficacy as anti-cancer drugs, such as PI3K inhibitors, exceeding the limits of the treatment as single agent. This evidence concerns the gene PIK3CA and neoplasm.